Avanir stock boosted by promising Zenvia data

A Phase III trial of Avanir Pharmaceuticals' closely-watched drug Zenvia showed that the drug relieved Pseudobulbar affect (PBA) in a subset of multiple sclerosis patients, sending Avanir's stock up as much as 16 percent. PBA is a neurologic disorder that occurs secondary to neurologic disease or brain injury, causing sudden and uncontrollable bouts of crying, laughing, or other emotional displays. Over the course of the 12-week study, Zenvia met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9 percent beyond placebo. A lower dose of the drug did not achieve statistical significance.

"We were very pleased that Zenvia demonstrated significant improvement in PBA episodes in the MS sub-population as well as encouraging proof of concept data in MS-related pain," said Randall Kaye, MD, Avanir's chief medical officer. "This is especially exciting given that the STAR trial was not powered to detect an efficacy signal in such a small number of patients. These data provide additional insight into the clinical utility of Zenvia and help shape our plans for future drug development."

This has been a week of good news for Avanir. Two days ago the company obtained a new patent for Zenvia, which will extend its commercial exclusivity period until well into 2025.

- check out Avanir's release
- here's the Reuters report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.